Lupin receives EIR from USFDA for Nagpur Facility

13 Apr 2020 Evaluate
Lupin has received the Establishment Inspection Report (EIR) after closure of the United States Food and Drug Administration (USFDA) inspection of its Nagpur, India facility. The inspection for the facility was carried out by the USFDA between January 6, 2020 and January 10, 2020.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2122.65 1.00 (0.05%)
29-Jan-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1589.30
Dr. Reddys Lab 1208.55
Cipla 1320.35
Zydus Lifesciences 890.20
Lupin 2122.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×